Clovis Oncology has warned it is “increasingly probable” that it will enter bankruptcy as revenues shrink and the regulatory outlook worsens for its only marketed drug, Rubraca.
The Bolder, CO-based specialist pharma company has been struggling for years to gain traction with Rubraca (rucaparib), the least favoured of three PARP inhibitors on the market, behind AstraZeneca/Merck & Co’s
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?